Nov, 2005

U.S.A.
News / Therapeutic Area News
FDA Approves Tarceva(R) in Combination with Gemcitabine Chemotherapy for Treatment of Locally Advanced, Inoperable or Metastatic Pancreatic Cancer; Tarceva Now Approved for Advanced Non-Small Cell Lung Cancer and Pancreatic Cancer
MELVILLE, N.Y. and SOUTH SAN FRANCISCO, Calif.--Nov. 2, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that the U.S. Food and Drug Administration...
Read More

Oct, 2005

U.S.A.
News / Therapeutic Area News
Cardiome and Astellas Initiate Act IV Study
Vancouver, Canada, October 19, 2005 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. today announced the initiation of an open-label...
Read More
U.S.A.
News / Therapeutic Area News
OSI Reiterates Confidence in Tarceva
MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 12, 2005--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today reiterated its confidence in the launch year performance and long-term prospects of its flagship...
Read More

Sep, 2005

U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Tarceva(R) Granted Approval in the European Union for the Treatment of Advanced Non-Small Cell Lung Cancer
MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 21, 2005--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the...
Read More
U.S.A.
News / Therapeutic Area News
FDA Advisory Panel Recommends Tarceva(R) Approval for Pancreatic Cancer; Committee Supports New Indication for EGFR Inhibitor Tarceva
MELVILLE, NY & SAN FRANCISCO--(BUSINESS WIRE)--Sept. 13, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that the Oncologic Drug Advisory Committee...
Read More